title: Microsphere technology: hype or help?
abstract: Initiation of effective topical therapy as early as possible within the disease course is associated with improved patient experiences and better therapeutic outcomes in most dermatological diseases. Additionally, patient adherence is associated with better outcomes and lower long-term treatment costs, while poor adherence is directly linked to poor treatment results and patient dissatisfaction. Local cutaneous irritation associated with topical drug formulations has been an historical challenge to therapy initiation and adherence. Retinoids and benzoyl peroxide-essential elements of topical acne treatment-are two of the drugs most commonly associated with application-site adverse events. Novel approaches to product formulation incorporating microsphere technology may improve treatment tolerability, encourage adherence, and contribute to better long-term therapeutic outcomes. Microsphere technology eliminates the rapid delivery of high concentrations of active drug to the application site and instead facilitates controlled release of potentially irritating drugs. It is associated with improved treatment outcomes and minimal irritation. Microsphere formulations of topical tretinoin and benzoyl peroxide currently on the market have demonstrated good efficacy and tolerability and are expected to encourage adherence and long-term therapeutic benefit.
authors: Indiana University School of Medicine, Indianapolis, Indiana; Mount Sinai Medical Center, New York, New York; DermResearch, PLLC, Louisville, Kentucky.
authors: Leon H
authors: LH
authors: Kircik
references: Cutis. 2006 Apr;77(4):251-5
references: 16706243
references: J Microencapsul. 1996 Sep-Oct;13(5):575-88
references: 8864994
references: J Clin Aesthet Dermatol. 2009 Sep;2(9):46-54
references: 20729960
references: Cutis. 1998 Feb;61(2 Suppl):11-21
references: 9787987
references: J Drugs Dermatol. 2010 Jul;9(7):805-13
references: 20677537
references: Clin Pediatr (Phila). 2010 Jan;49(1):54-9
references: 19738184
references: Micron. 2007;38(8):834-40
references: 17692528
references: Cutis. 2002 Nov;70(5):295-8
references: 12469785
references: Int J Dermatol. 2010 Apr;49(4):448-56
references: 20465705
references: J Dermatolog Treat. 2001 Sep;12(3):149-57
references: 12243706
references: Cutis. 2008 Nov;82(5 Suppl):12-6
references: 19202773
references: Clin Ther. 2007 Jun;29(6):1086-97
references: 17692723
references: Curr Drug Deliv. 2007 Apr;4(2):123-9
references: 17456031
references: J Drugs Dermatol. 2008 Jun;7(6):590-5
references: 18561594
references: Cutis. 2009 Feb;83(2 Suppl):4-15
references: 19363873
references: Aust Fam Physician. 2006 Jul;35(7):503-4
references: 16820822
references: Cutis. 2000 Aug;66(2):153-6
references: 10955199
references: J Am Acad Dermatol. 1991 May;24(5 Pt 1):720-6
references: 1869643
references: Int J Pharm. 2006 Feb 3;308(1-2):124-32
references: 16359833
references: J Am Acad Dermatol. 2003 Jul;49(1 Suppl):S1-37
references: 12833004
references: J Am Acad Dermatol. 2009 May;60(5 Suppl):S1-50
references: 19376456
references: J Drugs Dermatol. 2010 Aug;9(8):908-11
references: 20684140
references: Cutis. 2006 May;77(5):313-6
references: 16776288
references: J Drugs Dermatol. 2008 Aug;7(8 Suppl):s14-8
references: 18724650
references: Am J Clin Dermatol. 2006;7(4):231-6
references: 16901183
references: J Drugs Dermatol. 2009 Jul;8(7):657-61
references: 19588642
references: J Eur Acad Dermatol Venereol. 2006 Apr;20(4):370-9
references: 16643132